Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 31
1996 115
1997 115
1998 208
1999 213
2000 190
2001 198
2002 199
2003 233
2004 264
2005 264
2006 306
2007 351
2008 381
2009 338
2010 361
2011 364
2012 379
2013 397
2014 485
2015 438
2016 450
2017 407
2018 400
2019 316
2020 983
2021 729
2022 652
2023 74
Text availability
Article attribute
Article type
Publication date

Search Results

8,976 results
Results by year
Filters applied: . Clear all
Page 1
Nirmatrelvir Plus Ritonavir: First Approval.
Lamb YN. Lamb YN. Drugs. 2022 Apr;82(5):585-591. doi: 10.1007/s40265-022-01692-5. Drugs. 2022. PMID: 35305258 Free PMC article. Review.
Nirmatrelvir plus ritonavir (Paxlovid; Pfizer) is a co-packaged combination of nirmatrelvir and ritonavir tablets, intended for co-administration and developed for the treatment and post-exposure prophylaxis of coronavirus disease 2019 (COVID-19). ...Nirmatrelvir pl …
Nirmatrelvir plus ritonavir (Paxlovid; Pfizer) is a co-packaged combination of nirmatrelvir and ritonavir tablets, intended fo …
Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
Saravolatz LD, Depcinski S, Sharma M. Saravolatz LD, et al. Clin Infect Dis. 2023 Jan 6;76(1):165-171. doi: 10.1093/cid/ciac180. Clin Infect Dis. 2023. PMID: 35245942 Free PMC article. Review.
Molnupiravir is a nucleoside analogue, whereas nirmatrelvir is a SARS-CoV-2 main protease inhibitor, and ritonavir is a human immunodeficiency virus type 1 protease inhibitor. Drug interactions are a major concern for nirmatrelvir-ritonavir. Nirmatrelvir-ritonavi
Molnupiravir is a nucleoside analogue, whereas nirmatrelvir is a SARS-CoV-2 main protease inhibitor, and ritonavir is a human immunod …
Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.
Anderson AS, Caubel P, Rusnak JM; EPIC-HR Trial Investigators. Anderson AS, et al. N Engl J Med. 2022 Sep 15;387(11):1047-1049. doi: 10.1056/NEJMc2205944. Epub 2022 Sep 7. N Engl J Med. 2022. PMID: 36069818 Free PMC article. No abstract available.
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.
Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back D, Khoo S. Marzolini C, et al. Ann Intern Med. 2022 May;175(5):744-746. doi: 10.7326/M22-0281. Epub 2022 Mar 1. Ann Intern Med. 2022. PMID: 35226530 Free PMC article.
Nirmatrelvir-ritonavir (NMV/r) is now being used to treat high-risk patients with mild to moderate COVID-19. ...
Nirmatrelvir-ritonavir (NMV/r) is now being used to treat high-risk patients with mild to moderate COVID-19. ...
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S, Metzendorf MI, Kuehn R, Popp M, Gagyor I, Kranke P, Meybohm P, Skoetz N, Weibel S. Reis S, et al. Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2. Cochrane Database Syst Rev. 2022. PMID: 36126225 Free PMC article. Review.
BACKGROUND: Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID-19 in asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and death. ...Nirmatrelvir/ritonavir for preventing SARS-CoV-2 infection (PrEP and PEP) No studies …
BACKGROUND: Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID-19 in asymptomatic people or those with mild symptoms, …
Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.
Charness ME, Gupta K, Stack G, Strymish J, Adams E, Lindy DC, Mohri H, Ho DD. Charness ME, et al. N Engl J Med. 2022 Sep 15;387(11):1045-1047. doi: 10.1056/NEJMc2206449. Epub 2022 Sep 7. N Engl J Med. 2022. PMID: 36069968 Free PMC article. No abstract available.
Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week.
Abraham S, Nohria A, Neilan TG, Asnani A, Saji AM, Shah J, Lech T, Grossman J, Abraham GM, McQuillen DP, Martin DT, Sax PE, Dani SS, Ganatra S. Abraham S, et al. J Am Coll Cardiol. 2022 Nov 15;80(20):1912-1924. doi: 10.1016/j.jacc.2022.08.800. Epub 2022 Oct 12. J Am Coll Cardiol. 2022. PMID: 36243540 Free PMC article. Review.
Nirmatrelvir-ritonavir (NMVr) is used to treat symptomatic, nonhospitalized patients with coronavirus disease-2019 (COVID-19) who are at high risk of progression to severe disease. Patients with cardiovascular risk factors and cardiovascular disease are at a high risk of d …
Nirmatrelvir-ritonavir (NMVr) is used to treat symptomatic, nonhospitalized patients with coronavirus disease-2019 (COVID-19) who are …
Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2020 Oct 24;396(10259):1345-1352. doi: 10.1016/S0140-6736(20)32013-4. Epub 2020 Oct 5. Lancet. 2020. PMID: 33031764 Free PMC article. Clinical Trial.
BACKGROUND: Lopinavir-ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, and observational studies. ...These findings do not support the use of lopinavir-ritonavir for treatment of patients admitted to hos …
BACKGROUND: Lopinavir-ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, …
8,976 results